Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Amag Pharmaceuticals (AMAG)

Amag Pharmaceuticals (AMAG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Amag Pharmaceuticals 1100 WINTER STREET WALTHAM MA 02451 USA

www.amagpharma.com P: 617-498-3300

Description:

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the company's key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.Combidex', the company's other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.

Key Statistics

Overview:

Market Capitalization, $K 477,469
Shares Outstanding, K 34,725
Annual Sales, $ 327,750 K
Annual Net Income, $ -466,460 K
Last Quarter Sales, $ 52,760 K
Last Quarter Net Income, $ -13,240 K
60-Month Beta 0.89
% of Insider Shareholders 12.73%
Float, K 30,305
% Float 87.27%

Growth:

1-Year Return 41.90%
3-Year Return -1.79%
5-Year Return -48.21%
5-Year Revenue Growth 163.51%
5-Year Earnings Growth -3,947.06%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 11/13/20
Earnings Per Share ttm -2.30
EPS Growth vs. Prev Qtr 28.21%
EPS Growth vs. Prev Year 60.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 3-2 on 09/26/91

AMAG Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -16.92%
Return-on-Assets % -5.96%
Profit Margin % -142.32%
Debt/Equity 1.13
Price/Sales 1.45
Price/Cash Flow N/A
Price/Book 1.85
Book Value/Share 7.28
Interest Coverage -17.14
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar